Harrow, Inc. /
Melt Pharmaceuticals, Inc.
Harrow adds Melt Pharmaceuticals to its portfolio
Source for the buyer and target: Harrow, Inc.
For the buyer and target.
“On November 17, 2025, Harrow, Inc. (the “Company”) completed the previously announced acquisition of Melt Pharmaceuticals, Inc. (“Melt”) pursuant to the Agreement and Plan of Merger, dated September 24, 2025 (the “Merger Agreement”), by and among the Company, Harrow Acquisition Sub, Inc., Melt, and the stockholder representative.”
Published 18 Nov 2025
Open the sourceWhat happened
Harrow, Inc. completed its acquisition of Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing non-opioid, non-IV sedation therapies for medical procedures. [01]
Harrow paid approximately $4.3 million in cash as initial consideration for Melt’s remaining equity interests. Contingent regulatory and commercial milestone payments remain unchanged. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Harrow adds Melt Pharmaceuticals to its portfolio
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly